Future of Automated Insulin Delivery Systems
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level. All AID systems are impacted by CGM accuracy and future CGM devices must be shown to be sufficiently accurate to be safely incorporated into AID. In this article, we summarize recent achievements in AID development, with a special emphasis on CGM sensor performance, and discuss the future of AID systems from the point of view of their input-output characteristics, form factor, and adaptability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J., & Alva, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0378 · Cited by 685 · cited 2×
“Flashglucose monitoring (Abbott Diabetes Care, Alameda) represents a new ‘‘on-demand’’ application of subcutaneous glucose sensing technology, effectively using CGM technology for replacement of SMBG and has been approved for nonadjunctive use in Europe.(26,27) Flash-glucose monitoring could be regarded as CGM on dema…”
BackgroundSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“5% and reduced time in hypoglycemia by 44% as compared with baseline.(39) It should be noted that this study was designed to evaluate safety and was not a randomized controlled trial.”
BackgroundDiabetes: Models, Signals, and Control
Cobelli, C., Dalla Man, C., Sparacino, G., Magni, L., De Nicolao, G., & Kovatchev, B. P. (2009) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2009.2036073 · Cited by 511
Self-citationDagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471 · cited 1×
“The normal human pancreas secretes glucagon to defend against hypoglycemia, a system which is dysfunctional in type 1 diabetes.(41) The addition of glucagon to AID is attractive to counteract the slow offset of subcutaneous insulin, but adds to overall system complexity and cost.”
BackgroundHome Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450 · cited 2×
“%) compared with SAP.37 Adults used the AP system day and night for 12 weeks, whereas children and adolescents used the system overnight for 12 weeks.”
MethodClosed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342
Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors
Kovatchev, B. P., Gonder-Frederick, L. A., Cox, D. J., & Clarke, W. L. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1922 · Cited by 312
Self-citationNovel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Self-citationComing of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223 · cited 1×
“Since 2011, the number of published studies on this topic increased exponentially.(35) Overnight insulin automation was the first target for many research groups, given the high potential benefit of reducing nocturnal hypoglycemia without the complicating issue of meals.”
Background
Cited by
DeSalvo, D. J., Miller, K. M., Hermann, J. M., Maahs, D. M., Hofer, S. E., Clements, M. A., Lilienthal, E., Sherr, J. L., Tauschmann, M., Holl, R. W., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12711 · Cited by 233
“Robust clinical protocols, quality improvement and research efforts to optimize real-time CGM use are essential to ensuring durability of CGM use, facilitating automation of insulin delivery and improving glycemic outcomes.(9)”
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
The History, Evolution and Future of Continuous Glucose Monitoring (CGM)
Bender, C., Vestergaard, P., & Cichosz, S. L. (2025) · Diabetology · doi:10.3390/diabetology6030017 · Cited by 43
“These systems integrate CGM data with insulin pumps to automate insulin delivery based on real-time glucose readings [64].”
Hövelmann, U., Olsen, M. B., Mouritzen, U., Lamers, D., Kronshage, B., & Heise, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13562 · Cited by 28
Sarma, A. D., & Devi, M. (2025) · Hormones · doi:10.1007/s42000-025-00644-4 · Cited by 16
Metadata
- Authors
- Castle, J. R., DeVries, J. H., & Kovatchev, B.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-06
- Volume
- 19
- Issue
- S3
- Pages
- S-67-S-72
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2624565427
- Cited by
- 45
- References
- 18
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Future of Automated Insulin Delivery Systems. https://app.cochat.ai/papers/10.1089/dia.2017.0012
- The paper
- Castle, J. R., DeVries, J. H., & Kovatchev, B. (2017). Future of Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2017.0012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.